Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
List view / Grid view
A living material resembling sputum from CF patients can grow biofilms, enabling scientists to assess the effectiveness of antimicrobials.
Advancements in enzyme-activated near-infrared fluorescent probes hold promise for evaluating responses to enzyme-targeting therapies.
Protein released by C. burnetti interacts with antioxidising enzyme GPX4 to prevent cell damage and death.
Scientists found that CXCR4 protein expression outside of the uterus is important for pregnancy maintenance.
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
20 October 2023 | By Eurofins Discovery
Join this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. These cells demonstrate considerable promise for uncovering drug-induced perturbations to…
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
Researchers at Tokyo University of Agriculture and Technology, led by Dr Tomoaki Murakami, have uncovered a previously undocumented disease, fibrinogen Aα-chain amyloidosis, highly prevalent in Japanese squirrels, shedding light on its parallels with the human condition. Their findings offer new insights into amyloidosis and its potential implications for medical research.
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.